A recently published study showed that a freeze-dried platelet-derived product improved blood clotting in laboratory tests of blood samples from patients with severe thrombocytopenia, which is often caused by fetal and neonatal alloimmune thrombocytopenia (FNAIT), both before and after standard platelet transfusions.
The findings suggested that FPH could help support clotting in patients with thrombocytopenia, a condition characterized by low platelet counts and an increased risk of bleeding. Platelet transfusions are commonly used to restore clotting ability, but maintaining adequate platelet concentrate supplies can be challenging because donated platelets have a short shelf life, and availability may fluctuate.
Learn more about FNAIT therapies
The study, published in the journal Transfusion, evaluated the clot-supporting capacity of the freeze-dried platelet-derived hemostatic product (FPH) in blood samples from patients with very low platelet counts due to oncohematological diseases. Researchers collected blood samples from 29 thrombocytopenic patients before platelet transfusion.
A subgroup of 18 patients also provided blood samples several hours after receiving standard platelet concentrates. The researchers then added FPH to the samples outside the body and analyzed clot formation using a laboratory system called the total thrombus-formation analysis system 01 (T-TAS 01), which measures how efficiently blood forms clots under flow conditions.
The study found that FPH significantly improved clot formation measures both before and after platelet transfusion. In some patients, FPH appeared to further improve clotting even after standard platelet transfusions had already been given.
Researchers also found that FPH retained several important platelet surface glycoproteins involved in clot formation. These proteins may help the freeze-dried particles interact with damaged blood vessels and existing platelets to support hemostasis, the body’s process of stopping bleeding.
The authors also noted that FPH may expose patients to lower levels of human leukocyte class 1 (HLA-1) antigens than standard platelet transfusions because it uses smaller doses and appears less reactive with patient antibodies. Reduced HLA exposure may help lower the risk of alloimmunization, a process in which the immune system develops antibodies against transfused platelets.
Although FNAIT is primarily driven by incompatibility between platelet-specific antigens rather than HLA Class 1 antigens, alloimmunization also plays an important role in the condition.
Though the findings are promising, the researchers emphasized that the study evaluated FPH only in blood samples outside the body rather than in patients directly. Additional clinical studies will be needed to confirm safety and effectiveness in real-world settings.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
